Recommended in NCCN and ASCO clinical guidelines for CINV prevention30,31

  • SANCUSO is recommended in the National Comprehensive Cancer Network (NCCN) antiemetic treatment guidelines30
  • Use of SANCUSO complies with NCCN recommendation that choice of antiemetic is based on30:
    • Emetogenicity of the chemotherapy regimen
    • Individual patient factors (eg, partial or complete bowel obstruction, concomitant drug treatments, including opiates)
  • According to the American Society of Clinical Oncology (ASCO) antiemetic guidelines31, the granisetron transdermal patch can be offered to patients receiving multiday chemotherapy.
    • Delivers therapy over multiple days rather than a serotonin antagonist taken daily.
Learn how SANCUSO provides up to
5 consecutive days of CINV prevention